The invention relates to a compound of Formula (I): (A&prime；)x-(A)-(B)-(Z)-(L)-(D), wherein: (A) is heteroaryl or aryl； each (A&prime；), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A&prime；) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, aryl, arylalkoxy, alkyl, alkoxy, cyano, sulfonyl, amido, and sulfinyl； X is 0, 1, 2, or 3； (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B)； (Z) is &mdash；NH&mdash；； (L) is chosen from &mdash；CH2CH2&mdash；, &mdash；CH2CH2CH2&mdash；, and &mdash；CH2CH2CH2CH2&mdash；； and (D) is chosen from &mdash；N(&mdash；R1)-R2, &mdash；O&mdash；R3, and &mdash；S&mdash；R3, wherein: R1 and R2 are mutually linked to form a heterocyclic ring together with the nitrogen atom that R1 and R2 are attached to, wherein said heterocyclic ring has 0, 1, 2, or 3 substituents independently chosen from &mdash；NH2, &mdash；NH(C1-C6 alkyl), &mdash；N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, cyano, alkoxy, haloalkyl, and haloalkoxy, or R1 and R2 are independently chosen from &mdash；H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein the sum of substituents on R1 and R2 together is 0, 1, 2, or 3, and the substituents are independently chosen from &mdash；NH2, &mdash；NH(C1-C6 alkyl), &mdash；N(C1-C6 alkyl)(C1-C6 alkyl), and fluoro； and R3 is chosen from &mdash；H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein R3 has 0, 1, 2, or 3 substituents independently chosen from &mdash；NH2, &mdash；NH(C1-C6 alkyl), &mdash；N(C1-C6 alkyl)(C1-C6 alkyl), and fluoro； or an enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof. The compounds of the invention show inhibitory LSD1 activity, which makes them useful in the treatment or prevention of diseases such as cancer.
